Table 2 FDA approved Antibody-Drug Conjugates and selected others undergoing clinical development for cancer therapy
From: Targeted drug delivery for cancer therapy: the other side of antibodies
Generic name | Trade/code name | Target | Antibody source | Antibody isotype | Other manipulations | Conjugated to: | Clinical status | Indication |
|---|---|---|---|---|---|---|---|---|
Gemtuzumab ozogamicin | Mylotag® | CD33 | Mouse monoclonal | IgG4- kappa | Humanized | Calicheamicin | Approved 2000 WITHDRAWN 2010 | CD33+AML |
Brentuximab vedotin | Adcentrisâ„¢ | CD30 (TNFR) | Mouse monoclonal | IgG1- kappa | Chimeric | Monomethyl auristatin E (MMAE) | Approved 2011 | HL |
Trastuzumab emtansine | MCC-DM1/ T-DM1 | HER-2 | Mouse monoclonal | IgG1- kappa | Humanized | Maytansinoid DM1 | Phase III | HER-2+ MBC |
Inotuzumab ozogamicin | CMC-544 | CD22 | Mouse monoclonal | IgG4- kappa | Humanized | Calicheamicin | Phase III Phase II | NHL DLBCL |
Lorvotuzumab mertansine | IMGN901 | CD56 | Mouse monoclonal | IgG1- kappa | Humanized | Maytansinoid DM1 | Orphan Drug 2010; Phase II | SMLC, OC, MM |
------ | SAR3419 | CD19 | Mouse monoclonal | IgG1 | Humanized | Maytasinoid DM4 | Phase I | NHL |